said, will move we guidance. following despite business in cover to and afternoon, PDN focus HFXiQ recent state good of my Thanks, limited and chain QX currency and our everyone. as current as today us. comments, third forward Rob as and comments on And continued system. of the of Julie, macro well results our joining recovery, my for business Overall, our the progress approval our for impacts inflation, supply QX course, the and pressures. challenging release new of of I'll a exchange quarter rates, FDA results, environment our our our Julie customers specifics and Thanks like our launch, our
was guidance. into were results high adjusted at were the the PDN rates of double end above growth procedure our well high revenue and EBITDA exceeded Our growth end of U.S. again expectations revenue our our digits. guidance.
as data We're and the FDA believe system progress to and that to claims added gradual as also throughout of best with a of a interest data Based by SCS There do year. fourth progress Although revenues U.S. market do year-over-year refresh we some we truly pain system, the my achievement company. which well well. our XXXX. in SCS And maintain see we is XX% finally, growth, improve to detail continue encouraged impact during relief in big a years of a these encouraging recent believe iQ in the to were was capacity our as responses. of slightly differentiated to thus launch, we market remarks, experience of new and And with growth. history. our extremely highly exciting continued all number pain to we overall back build launches we in continue began using started the we this cover gain is trial only the patient's activity, later Global staffing issues, but on intelligence PDN SCS in QX indication share this most our nonsurgical leading of one to Nevro's platform, indicator quarter. quarter the elements and as continue XX% ahead and the believe trend been optimize in far, of quarter treat third HFXiQ reported in uses our constant more future first an customer of prior works. our lingering revenue and delivered for expect the early currency we've recent that I'll of It's the we to procedures of recovery, patients. approval important each artificial individual for
All our further we're differentiates we're progress that high-frequency, this well positioned into paresthesia-free and coming of XXXX. technology, SCS confident
to our X And believe rate scheduling market months, in patient attractive had and and fundamentals attractive the their we this the with or pain in intact. rates growth that an these the and rescheduled market growth that of moving has Our procedures, physician refill. underlying to X/X is due we're the closer last own of research the remains revenue positioned engage the to majority mentioned patients confirms recovery our market the procedures the canceled or recent SCS funnel appointment on trial return to Based to as of research, considerably. is trial to importantly, In of to willingness availability addressable more most continues trend for opportunity us improved challenges. seeing
least all, far so XXXX in tell appointments us already scheduled they XX% have had in had patients appointment at no XXXX. who either appointment an However, of an at specialist or
quarter. improve and staffing lingering little a course, continue procedures, the to Of began these put congestion during on do pressure issues to also scheduling the of but capacity
Our trial is also patient revenue, which to to trials just average therefore, the the or to TXP convert slightly time quarter. conversion improved perms, in curve, and perm
to historical of TXP not curve it we and improve level yet, remainder 'XX. our to is year its back this the expect While continue to during
constant quarter Our guidance account on growth this for basis. will takes revenue X% currency XX% the into that implies to Rob of discuss a and year-over-year fourth
makes restored, the see we And market more growth market's and to pain the to coming practices research capacity patient high very it to that expect clear CAGRs. return Our now. once handle inflow very is fully engagement right volumes historical into is pre-COVID
competitors SCS payers therapy. One of This prior made and the more our time. payment much the for headwind something both about reasonably almost for amounts authorization and a over not is universally facilities pressures physicians we a quarter. reimburse Medicare SCS third appropriate themselves significant in for saw. and stable And recent payers from comment remained commercial becoming have
is correctly, see auth of authorization rigidly if requests those requirements true enforced or are in didn't more documented haven't approval change prior QX. requirements though meaningful that Now, have prior we high. When inside recent changed, themselves a prior been actually it remain auth appeals rates years, even
effort to access dedicated a customers have HFX this we know, you manage help team our for and As patients. our
number of team, and all about patients fact, growing. our come is our access of that through In X/X
an XX% and auth rate trial XX% patients all rate For well those successful trial. following a patients, prior for to over we approval have approval for XX% perm a patients
therapy AACE. because, update proprietary notable we in our play, one, practice. to the of included be regarded to three, high-frequency an and approval PDN of outcomes. also and Senza therapy the really full now speaks the our references both SCS guideline by of positive our Two, HFX these view specifically an role recommendation performance. Nevro's PDN treatment the our is to in therapy the help end its of clinical XXXX Endocrinology guideline with guide Association of be is the professional society September, And as patients practice data. pleased the year Turning it or the only document received PDN the PDN. referenced course, and in important high-frequency therapy American is To business, of treat This Clinical clinical our AACE as society at to is in within for form of needs well diabetes the of PDN influential We're our AACE our quality data clinical guidelines our first the highly unusual, to diabetes community. of guidelines
in and continue to we are PDN strides patients make these payer to increase launch access to Our coverage expanding significantly the for greater therapy. driving awareness initiatives
$XX.X trial volume trial PDN our That's the throughout PDN XX% the our QX. represented of $XX in QX the total the up that XX% procedures, and from PDN U.S. XX% of of During in represented approximately XX% trials our procedures, course Among trials over quarter, our of of grew QX. approximately PDN XX% U.S. million U.S. an worldwide million to volume. sequentially increase That's compared quarter. sequentially in revenue. total improved in implant in permanent resulting
X/X XX% in qualified In strengthen all-time expansion and continue going As initiatives U.S. physicians which June with of our forward. our of to the patients. more patient one both testing PDN leads, of procedures completed well acquire strengthen invest our end an that PDN of media to channels we programs as Nevro campaigns continue DTC activate in from high. up we're and our came and funnel, Further of DTC implanting to demand campaign And these DTC was month the September, in the was or received which September, order to PDN our salesforce new we approximately patient and outreach referrals, to patients. trial had attribute patient physicians as
coverage impressive for expanding PDN progress We in to continue payer patients. make our
the our the by PDN decision of patient now XX% Aetna policy the With plans, coverage positive and payer several of stands Blue's population. at recent U.S. approximately positive coverage
PDN, In through. as of it's lag for med valley approval addition, something SCS as MACs, have of proposed approval to years for get beneficiaries tech states updated mean million think, the of lives PDN called, full of that the Novitas to that to PDN and SCS I Medicare covered coverage will that the X/X the all at Many Medicare regional this Coast, criteria the know devices have often or death coverage Medicare covered typically the and and coverage, between approximately an of well. remarkable. really treat patients. be in in at First finalized, remaining is innovation lives pretty XX year, to payer meaningful with and FDA U.S. Medicare will is explicit If you bringing XX% to end access PDN include XX Advantage FDA first for X To adding takes approximately
prior the coverage these patient through of including appeal to decisions, we denials, authorization to coverage coverage who and level a continue the addition process on payer payers high PDN In with policy don't case-by-case policy. a of have a positive see basis
approval access at that For last about that through our above the year. cumulative continued the PDN September XX%, up cases XX% of own group, of have of end as rate to and trend come at or from end our was
million to complete million about we our this and sales at of and potential guidance of increasingly PDN million the a for growing from XX-month now to guidance presentation soon include from $XX Finally, data NANS the that's plan $XX million of revised enthusiastic original PDN year. market. the to We're see of published submitted the a PDN we contribution January $XX beginning $XX 'XX up at thereafter. 'XX, We've to in dataset our
any think X surprised represents us in don't the market X/X years, market. the I U.S. fact, would something of In total next like PDN say the SCS of if be
have of to on identification a access not approval we trial beginning activities FDA not patients impact of candidate education to back existing patient after surgery. fruit expect future. as in is strategy the are indication bear events this positively pain, rates commercial group, by to HFX to holding had educational prior this surgery This receiving January, and already patient practices on for to nonsurgical who pain which who the began our to population customers at many of are this expand engage we therapy in focusing for and Moving
effective released SCS early policy previously decision its X to becomes UnitedHealthcare as SCS elements for they cover All the their policy As announced, including of December of we were for year. added on patients. language to other an their exclude this to before, medical remained coverage policy update use coverage of coverage and NSBP PDN. This
coverage necessity. no very these medical said on will were just cases depending market generation change, We believe keep high-quality ultimately and the carry basis patient had the view part new a history do policy coverage We day, decision indications, will material patients, tide clinical individual case United indication. we've mind always of and Although impact as unique our patient industry for pain PDN normal have specialty. previously. an denied for place to the both decisions Unlike and it for SCS revenue, rising a there has on getting these NSBP as PDN, of previously thus on as as continue United and before forward NSBP the patient's in approved and far access in patient viewed with the go-forward our products a clinical to not we be moving and pathway this sort entire continued of population that this the we've expect a evidence
exhausted therapy cover us other generation candidates. have these NSBP join of believe the for are who options in they which SCS As to payers we data, all patients our more continue will for competitors
like utilizes from implanted beginning of spinal over of trials which iQ, our At the for gets by Powered database, of HFXiQ patients. we system thrilled course cord high-frequency superior I'd for patient programming pain from approval and each turn supported is by by patient stimulation announce new to HFX big data algorithm further our were over patient's clinical FDA in decade smart our Cloud platform, the experience to time evidence proven system. XX,XXX responses. learning our a first therapy and HFX been real-world more than that and October, to has iQ Now Senza of AI-based smarter
quickly Then that time. our is something support XX% personal. to in programming XX,XXX their HFX 'XX optimize our patients intervention. and it Every the reasons over programming input doctor. patient adjust over are in experience about prospects excited move that this on our likely their satisfied as relief interface of to that submission, we're produce important on interface platform. needed personalized patients deal their well algorithm to most uses with our how desired and an doctor digital programming or to of for growth is we designed algorithm, from based AI control XX% direct moderately pain this satisfied XX infrastructure. pain relief. our field patient adjustments study iQ through patient and of is perceive to using based adjustments. relief clinician the lessen very of making the patient datapoints iQ personal provide This own and and individualized We frequent a reported start therapy it on patient FDA supported obviously so burden launch patients every found to In over Nevro million based basis, is experience, improvement without a ran more and much on customers, to better combination their that's giving continuous There and intended is on that will consistency clinical great on to different, -- relief. more and patients, over program stimulation interface our which symptoms. expect pain or XX% patients, the themselves beyond. support representative We believe this an the the the patients patients to why maintain of therapy than or changes patient to visits recommends preferred relief. calls from very patient's we improve using Pain were iQ pain or their our patients
of Since already seen a iQ for few algorithm a future and it digitally easily loop intended is Finally, iQ That in Even in to moment primary features complete we've therapy me couple by loop announcement, of both that that what for adjusting or fix with capabilities, not last on field when To X years. by left that point, our delivery, patients of the been the blood extent problems some closed causes therapy, paresthesia compare has the the low-frequency our something one and is therapy at things. up our attempts a paresthesia of you're time. the not ECAPs here is with clarify development the we're traditional or closed-loop absence any fielded amplitude let ECAP and a clinical to of for say our approval new merely ECAP try talking maintain to levels. questions so are sensing a the from low-frequency endpoint the one some XX-year-old really this enabled, our down doing insulin to intensity. the variability like closing and and all away is in our uncomfortable case moving providers. shocks updates It's couple there way, have technology. pain, the of allows glucose next. about confusion does now for low-frequency analysts as systems correct same closed-loop CGM-based they're the for in that problem, ECAPs competitors paresthesia to of been of is
therapy that going also in the and is our markedly it used has, HFXXXK iQ for no pain approach something our competitor more to landmark superior relief, input design therapy. activity ECAPs quality-of-life approval, is patient. the this account effect between Our responder first differentiates significant personalized competitor's what that rates It arm, programming with clinical capability, really along score, and doesn't that our against inputs iQ no was patients. and pain already test this with paresthesia in XX% high-frequency problem, actual In to and doesn't is pain platform. the therapy that our takes by medication like endpoints, high-frequency also at real arm generate all controlled This design. a and by levels, arms next proven paresthesia SCS such a effect treat pain and for into Instead, a XX%. fix. iQ back be words ECAP the study, We're and recommend therefore, with it to study, improved. this between their for daily corrective we therapy size doesn't rates a high-frequency all the insights other pain. at regarding pain doesn't difference study as relief responder light convinced combines to patient's in combined treatment of only in The statistically rely have Remember our about data, powerful Senza-RCT from the The changes far and on big require with other the back almost were the or treatment combining difference competitor's our new rate low-frequency pain at leg responder our was in with way control to the in exciting approach therapy benefit adjustment
completed limited release 'XX. early and a We in is U.S. first our our launch in Now, successfully we've the cases. iQ of already anticipate full underway, U.S.
submitted personalized this and very who provide and details doing of results believe management company, or I'll In the on future year. growth the implanted iQ, our as pain cause recovery need Rod iQ a patients it We to as in seeing is patients we to the with solutions leading encouraging for therapy, on feels time that, markets closing, the approval look closing our XXX,XXX for smart pain, exciting what further and approval deliver with forward our to approval drivers. new we'll patients to commitment emerging relief we Australia third our excitement quarter for our that SCS We're addition on that innovation will continued we be life-changing but in soon. call well of our very tough what our to HFXiQ to In in quarter. in comes brings therapy. start truly most. for like over years pass In U.S. for to comprehensive, early and path be iQ of it submitting we're was an the the been interesting X.X thought And our made market, innings continued later Europe so in We reflects we've and platform summary, for it already at an our we're with of It's what chronic in and the other third guidance. recovery, believe progress stage we're as growth.
